Compare Stocks → It’s now possible to know the win rate of every trade… BEFORE you take it! (From WealthPress) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ALTNASDAQ:AVDLNASDAQ:MTEMNASDAQ:RAPTNASDAQ:SPPI Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$7.25+0.7%$9.31$2.09▼$14.84$513.95M0.055.30 million shs676,215 shsAVDLAvadel Pharmaceuticals$17.99+1.0%$15.81$9.50▼$18.85$1.63B1.61.21 million shs150,099 shsMTEMMolecular Templates$1.64+2.5%$2.62$1.40▼$9.45$8.81M1.1551,893 shs16,641 shsRAPTRAPT Therapeutics$8.19+5.0%$9.23$6.86▼$27.35$285.01M0.471.14 million shs115,366 shsSPPISpectrum Pharmaceuticals$1.03$1.01$0.32▼$1.57$211.41M2.151.93 million shsN/A7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune+1.69%+4.50%-16.76%-22.83%+37.93%AVDLAvadel Pharmaceuticals+0.91%+2.53%+9.73%+28.85%+77.49%MTEMMolecular Templates-3.05%+7.07%-30.57%-55.40%-73.21%RAPTRAPT Therapeutics-1.27%-1.64%-7.14%-69.16%-58.33%SPPISpectrum Pharmaceuticals0.00%0.00%0.00%0.00%+16.78%Exposed: 10 CENT Crypto to Explode April 20th? (Ad)The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALTAltimmune1.3698 of 5 stars3.31.00.00.03.11.70.0AVDLAvadel Pharmaceuticals1.9226 of 5 stars3.51.00.00.03.01.70.6MTEMMolecular Templates1.0824 of 5 stars0.02.00.04.61.14.20.0RAPTRAPT Therapeutics4.0118 of 5 stars4.32.00.03.61.11.70.6SPPISpectrum PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune2.67Moderate Buy$15.00106.90% UpsideAVDLAvadel Pharmaceuticals3.00Buy$22.5725.47% UpsideMTEMMolecular TemplatesN/AN/AN/AN/ARAPTRAPT Therapeutics2.50Moderate Buy$25.67213.39% UpsideSPPISpectrum Pharmaceuticals2.00HoldN/AN/ACurrent Analyst RatingsLatest ALT, RAPT, SPPI, MTEM, and AVDL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2024RAPTRAPT TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral4/9/2024AVDLAvadel PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.004/1/2024ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $12.003/28/2024ALTAltimmuneB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.003/27/2024RAPTRAPT TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$15.00 ➝ $13.003/5/2024AVDLAvadel PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $22.003/5/2024AVDLAvadel PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$18.00 ➝ $23.003/5/2024AVDLAvadel PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$27.00 ➝ $29.003/5/2024AVDLAvadel PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$21.00 ➝ $25.003/5/2024AVDLAvadel PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $22.002/22/2024RAPTRAPT TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$61.00 ➝ $10.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$430K1,195.24N/AN/A$2.75 per share2.64AVDLAvadel Pharmaceuticals$27.96M58.28N/AN/A$0.98 per share18.36MTEMMolecular Templates$57.31M0.15N/AN/A$0.78 per share2.10RAPTRAPT Therapeutics$1.53M186.28N/AN/A$4.27 per share1.92SPPISpectrum Pharmaceuticals$10.11M20.91N/AN/A$0.15 per share6.87Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$88.45M-$1.65N/AN/AN/A-20,780.75%-44.77%-40.72%5/9/2024 (Estimated)AVDLAvadel Pharmaceuticals-$160.28M-$2.04N/A21.16N/AN/A-198.06%-84.51%5/2/2024 (Estimated)MTEMMolecular Templates-$8.12M-$1.55N/AN/AN/A-14.18%-9,335.53%-20.51%5/20/2024 (Estimated)RAPTRAPT Therapeutics-$116.80M-$3.04N/AN/AN/AN/A-63.14%-55.48%5/9/2024 (Estimated)SPPISpectrum Pharmaceuticals-$75.40M-$0.36N/A14.71N/AN/A-218.44%-66.16%N/ALatest ALT, RAPT, SPPI, MTEM, and AVDL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/29/2024Q4 2023MTEMMolecular Templates-$2.10-$0.73+$1.37-$0.73N/A$7.02 million3/27/2024Q4 2023ALTAltimmune-$0.35-$0.33+$0.02-$0.12N/A$0.04 million3/7/2024Q4 2023RAPTRAPT Therapeutics-$0.85-$0.80+$0.05-$0.80N/AN/A3/4/2024Q4 2023AVDLAvadel Pharmaceuticals-$0.28-$0.32-$0.04-$0.29$17.41 million$19.45 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/AAVDLAvadel PharmaceuticalsN/AN/AN/AN/AN/AMTEMMolecular TemplatesN/AN/AN/AN/AN/ARAPTRAPT TherapeuticsN/AN/AN/AN/AN/ASPPISpectrum PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmuneN/A17.2617.26AVDLAvadel PharmaceuticalsN/A3.643.36MTEMMolecular TemplatesN/A0.970.97RAPTRAPT TherapeuticsN/A7.417.41SPPISpectrum PharmaceuticalsN/A2.712.38OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%AVDLAvadel Pharmaceuticals69.19%MTEMMolecular Templates95.47%RAPTRAPT Therapeutics99.09%SPPISpectrum Pharmaceuticals21.67%Insider OwnershipCompanyInsider OwnershipALTAltimmune4.10%AVDLAvadel Pharmaceuticals4.00%MTEMMolecular Templates18.70%RAPTRAPT Therapeutics6.60%SPPISpectrum Pharmaceuticals2.70%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune5970.89 million67.99 millionOptionableAVDLAvadel Pharmaceuticals15490.58 million86.95 millionOptionableMTEMMolecular Templates1115.37 million4.37 millionNo DataRAPTRAPT Therapeutics13134.80 million32.50 millionOptionableSPPISpectrum Pharmaceuticals86205.25 million199.70 millionOptionableALT, RAPT, SPPI, MTEM, and AVDL HeadlinesSourceHeadlineSpectrum Pharmaceuticals gets grant for crystalline form of quinazoline compound and hydrochloride saltspharmaceutical-technology.com - April 24 at 10:28 AMAssertio Holdings, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information - ASRTmarkets.businessinsider.com - February 21 at 11:54 PMLevi & Korsinsky Notifies Shareholders of Assertio Holdings, Inc.(ASRT) of a Class Action Lawsuit and an Upcoming Deadlinemarkets.businessinsider.com - February 21 at 1:34 PMLost Money on Assertio Holdings, Inc.(ASRT)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinskymarkets.businessinsider.com - February 8 at 2:32 PMAssertio Holdings, Inc. (NASDAQ: ASRT) INVESTOR ALERT: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Actionmarkets.businessinsider.com - February 5 at 2:12 PMGlancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Assertio Holdings, Inc. (ASRT)stockhouse.com - February 1 at 1:26 PMCLASS ACTION NOTICE: Berger Montague Encourages Assertio Holdings, Inc. (ASRT) Investors to Inquire About a Securities Fraud Class Actionmarkets.businessinsider.com - February 1 at 1:16 AMSHAREHOLDER ALERT: Levi & Korsinsky Notifies Assertio Holdings, Inc.(ASRT) Investors of a Class Action Lawsuit and Upcoming Deadlinestockhouse.com - January 30 at 10:18 AMINVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Assertio Holdings, Inc. (ASRT) Investorstmcnet.com - January 26 at 6:41 PMLobbying revenues continued climbing amid stalled Hill actionpolitico.com - January 23 at 7:48 PMINVESTOR ALERT: Levi & Korsinsky Notifies Shareholders of Assertio Holdings, Inc.(ASRT) of a Class Action Lawsuit and an Upcoming Deadlinestockhouse.com - January 13 at 10:52 PMEye Melanoma Market Size Worth USD 9.56 Billion in 2032 | Emergen Researchfinance.yahoo.com - January 12 at 6:07 AMVaccine Adjuvant Market Size Worth USD 1.75 Billion in 2032 | Emergen Researchfinance.yahoo.com - January 10 at 10:13 AMSHAREHOLDER ALERT: Potential Recovery for Assertio Holdings, Inc. (ASRT) Investorsmsn.com - January 9 at 8:33 AMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Assertio Holdings, Inc. - ASRTmarkets.businessinsider.com - November 9 at 7:46 PM$19.30+ Bn Neutropenia Treatment Market to Grow at 5.4% CAGR, Globally, by 2027pharmiweb.com - November 8 at 7:16 PMDisney offers streaming service discount amid Spectrum blackoutctpost.com - September 8 at 6:23 PMAnalyzing Spectrum Pharmaceuticals Inc. (SPPI) After Recent Trading Activityknoxdaily.com - July 31 at 5:06 PMSpectrum Pharmaceuticals Inc. [SPPI] CFO makes an insider sale of 32,387 shares worth 35,496.knoxdaily.com - July 28 at 10:55 AMBuy Spectrum Pharmaceuticals For Exposure To Assertio Holdingsseekingalpha.com - July 24 at 6:02 AMPotential Price Increase for Spectrum Pharmaceuticals Inc. (SPPI) After Recent Insider Activityknoxdaily.com - July 19 at 7:14 PMNegative sentiment towards SPPI reflected by a jump of 6.23% in short interestknoxdaily.com - July 14 at 9:14 PMSpectrum Pharmaceuticals Inc. [SPPI] Investment Appeal on the Riseknoxdaily.com - July 11 at 7:15 PMSpectrum Pharmaceuticals (NASDAQ: SPPI)fool.com - July 8 at 8:10 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesHigher Oil Prices Could Give NextEra’s Stock Earnings a BoostApril 24, 2024 10:40 AMView Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost3M Spun Off Its Health Division, Is It Still A Buy?April 4, 2024 7:47 AMView 3M Spun Off Its Health Division, Is It Still A Buy?4 Dividend Aristocrats Trading at a DiscountApril 1, 2024 6:10 AMView 4 Dividend Aristocrats Trading at a DiscountCan Altimmune get its GLP-1 Drug to Market Before Cash Rush Out? April 9, 2024 6:07 AMView Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out? Undervalued UnitedHealth Group Won’t Be For LongApril 16, 2024 10:53 AMView Undervalued UnitedHealth Group Won’t Be For LongAll Headlines Company DescriptionsAltimmuneNASDAQ:ALTAltimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Avadel PharmaceuticalsNASDAQ:AVDLAvadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.Molecular TemplatesNASDAQ:MTEMMolecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company primarily develops therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.RAPT TherapeuticsNASDAQ:RAPTRAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb CompanySpectrum PharmaceuticalsNASDAQ:SPPISpectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.